Articles tagged with Mesothelioma
A phase Ib trial demonstrated that combining immunotherapy with live bacterium CRS-207 and chemotherapy resulted in a 94% disease control rate and 59% response rate in patients with malignant pleural mesothelioma. The therapy also showed good immune activation and synergistic efficacy with chemotherapy.
Researchers have discovered a new drug, HRX9, that targets the HOX gene family and induces apoptosis in mesothelioma cells. The study found that treatment with HRX9 resulted in complete loss of tumor blood vessels and widespread cancer cell death, offering new hope for patients.
Scientists have identified a spectrum of genetic alterations, including some that may be clinically actionable and others that could improve diagnostics and screening for patients. The study's findings suggest targeted therapies and immunotherapies could be effective treatments for mesothelioma.
Researchers developed a new test that detected mesothelioma 4-10 years before symptoms appeared, using a specific protein marker. The ONCOblot test detected the ENOX2 protein in serum samples from asbestos-exposed individuals, paving the way for earlier cancer detection and potentially reducing deaths.
Researchers suggest significant improvements in mesothelioma staging by incorporating tumor weight and volume into the current TNM system. This could lead to more accurate prognoses and personalized treatment plans for patients.
Researchers at the University of Hawai'i Cancer Center found that aspirin can inhibit the growth of mesothelioma by blocking HMGB1. This could lead to improved survival rates for patients with this aggressive cancer, which kills around 3,200 people annually.
In the ATREUS trial, 41.2% of patients treated with trabectedin in second line showed improved survival and median progression-free survival at 12 weeks. The study adds to scarce evidence-based science in this disease, warranting further investigation.
A new study from the University of Pennsylvania School of Medicine found that pembrolizumab, a PD-1 inhibitor, shrank or stabilized tumors in most patients with pleural mesothelioma. The medication was safe and showed promise for treating this rare and deadly form of cancer.
Researchers found higher proportions of women and young adults dying of mesothelioma in two counties encompassing Las Vegas, suggesting naturally occurring mineral fibers are a contributing source. The study highlights the need for more research to reduce exposure.
Researchers found elevated levels of malignant mesothelioma cases in southern Nevada counties due to environmental exposure to carcinogenic mineral fibers. The incidence is higher in locations with known industrial exposure, with a male-to-female ratio of 2:1 in affected counties.
A recent study found that high-dose radiotherapy did not improve survival rates or delay local relapse in patients with malignant pleural mesothelioma who had undergone chemotherapy and surgery. However, researchers discovered that about 20% of patients expressed the PD-L1 protein, which could be targeted with immunotherapy treatments.
Researchers have discovered that curcumin and peptides can increase levels of protein inhibitor PIAS3, which combats the progression of mesothelioma. This finding suggests that PIAS3 expression positively affects survival in mesothelioma patients, offering a potential therapeutic strategy.
A proportion of idiopathic pulmonary fibrosis (IPF) cases may be linked with unknown asbestos exposure according to the results of a new study. This would mean that current treatment strategies for IPF need to be altered as people with a history of asbestos exposure are not currently eligible for new treatments.
Researchers at Penn Medicine will conduct a clinical trial on patients with malignant pleural mesothelioma to test the efficacy of photodynamic light therapy (PDT). The study aims to understand how PDT works in the body and what can be done to improve its response.
Researchers at Penn University's Center for Environmental Toxicology will study asbestos exposure pathways and develop methods for bioremediation. The study aims to identify factors that increase the risk of mesothelioma and determine if genetic or environmental factors play a role.
A new approach dubbed SMART has been shown to more than double three-year survival rates for mesothelioma patients treated with radiation therapy followed by surgery. The treatment approach, which involves an accelerated five-day course of intensity-modulated radiation therapy, reduces the risk of recurrence and improves quality of life.
Researchers found that posterior intercostal lymph nodes have predictive power for mesothelioma patients, with patients without cancer in these nodes having significantly longer overall survival rates. The study suggests including these lymph nodes in the mesothelioma staging system.
Researchers have identified Ephrin B2 as a promising target for treating malignant pleural mesothelioma, a rare and aggressive form of lung cancer. The study found that EPHB2 is significantly overexpressed in tumor tissue compared to normal peritoneum, suggesting its potential as a biomarker for early diagnosis and treatment.
A study analyzing the International Mesothelioma Interest Group (IMIG) staging system for malignant pleural mesothelioma (MPM) reveals areas for potential revision. The current system distinguishes among T and N categories, but qualitative T descriptors may not be applicable to clinical staging.
Researchers have discovered a specific marker, fibulin-3, that is four to five times higher in the plasma of patients with mesothelioma compared to those exposed to asbestos. The protein demonstrates high sensitivity and specificity for diagnosing mesothelioma, potentially leading to earlier treatment and improved patient outcomes.
A panel of 13 blood proteins has been identified as potential biomarkers for detecting malignant mesothelioma, a rare and aggressive form of lung cancer linked to asbestos exposure. The discovery could lead to the development of more accurate and less invasive diagnostic tests, improving patient outcomes.
A study published in the Journal of Thoracic Oncology found that patients with low thymidylate synthase (TS) levels and high fibroblast growth factor stimulator (FPGS) levels respond better to pemetrexed treatment. This combination predicts longer survival durations.
Researchers have identified a microRNA, miR-625-3p, that can accurately diagnose malignant pleural mesothelioma with an accuracy of 82.4%. Additionally, high-dose radiotherapy has shown promising response rates for patients with disease confined to one side of the chest.
A recent study published in the Journal of Thoracic Oncology suggests that pleurectomy/decortication (P/D) is a superior approach to extrapleural pnemonectomy (EPP) for patients with early-stage malignant pleural mesothelioma. P/D resulted in significantly better survival rates and lower mortality and morbidity compared to EPP.
A study published in Nature Genetics found that individuals with mutations in the BAP1 gene are susceptible to developing mesothelioma and melanoma. The research suggests that the BAP1 gene mutation may be involved in multiple cancer types, including breast and ovarian cancer.
A new study reveals that roads in North Dakota contain high levels of the cancer-causing mineral erionite, which can increase the risk of developing mesothelioma. The research team found that airborne concentrations of erionite in North Dakota were comparable to those found in Turkish villages with high mesothelioma rates.
The UH Cancer Center has received a significant gift to accelerate mesothelioma research, with scientists working on developing new therapies to prevent and treat the disease. Recent breakthroughs have shed light on potential causes, including exposure to erionite particles found in airborne asbestos.
Researchers found that temsirolimus strongly blocked mTOR-mediated signals and had a cytostatic effect on all mesothelioma cells. The study suggests using mTOR inhibitors as a novel anti-mesothelioma strategy, particularly in combination with chemotherapy.
Researchers found significant exposure to erionite in North Dakota roads, comparable to affected Turkish villages. The mineral poses health risks through inhalation, prompting cautionary measures and potential preventive programs.
The Lancet criticizes Canada and Quebec governments for exporting asbestos, a cause of deadly mesothelioma, to developing countries. The export will continue due to a loan guarantee, sparking protests and concerns about the exploitation of vulnerable populations.
Researchers discovered that asbestos exposure leads to the release of high-mobility group box 1 protein (HMGB1), which promotes tumor growth and inflammation. Elevated levels of HMGB1 in patients exposed to asbestos may enable simple serological testing to identify at-risk individuals.
A new vaccine has been proven safe and effective in treating mesothelioma, a rare cancer associated with asbestos exposure. The vaccine uses the patient's own dendritic cells to induce a T-cell response against mesothelioma tumors.
A new technique measuring pleural fluid mesothelin levels shows great promise in diagnosing mesothelioma. The study found that patients with mesothelioma had significantly higher levels of mesothelin than those with other conditions, allowing for a more accurate diagnosis.
Researchers conclude that adding chemotherapy to active symptom control does not improve overall survival or quality of life for mesothelioma patients. However, exploratory analyses suggest that vinorelbine may merit further investigation.
Scientists have established a mouse model for human malignant mesothelioma, an aggressive cancer originating from the mesothelial lining of the pleural cavity. The model closely resembles human MM, allowing researchers to study disease onset, progression, and test new therapeutic strategies.
A prospective study of Turkish villagers found a significant association between long-term erionite exposure and an increased risk of developing pleural mesothelioma. The study, conducted over 23 years, revealed annual incidence rates significantly higher in erionite-exposed villages compared to a control village.
A new study found that Californians exposed to low levels of naturally occurring asbestos are at higher risk for malignant mesothelioma. The research analyzed 2,908 cases over 10 years and found that people living close to asbestos source rocks had a greater chance of developing the disease, despite lower occupational exposure.
A new study found that elevated blood levels of osteopontin are associated with asbestos-induced cancers, particularly pleural mesothelioma. The protein's levels can serve as a potential biomarker for early detection and monitoring of individuals at risk due to asbestos exposure.
Researchers found a clear link between mesothelioma and residential proximity to ultramafic rock, the source of naturally occurring asbestos. The odds of developing mesothelioma fell by 6.3 percent for every 10 kilometers from an asbestos source.
Researchers found no detectable levels of SV40 in 69 tumors tested using a highly sensitive assay. The study's protocol aimed to eliminate possible contamination from DNA vectors used in laboratories worldwide.
A recent study by Memorial Sloan-Kettering Cancer Center researchers used multiple methods to detect SV40 DNA, RNA, and protein in human pleural mesothelioma samples, finding no evidence of a significant role for SV40. The team also discovered that common laboratory plasmid vectors may be causing false-positive results in assays.
A new blood test detects mesothelioma at an early stage, potentially leading to improved patient outcomes. The test uses soluble mesothelin-related proteins (SMR) as a biomarker, which can detect the cancer several years before symptoms appear.
A new blood test has been developed to detect mesothelioma, a type of cancer caused by asbestos exposure. The test, which identifies specific molecular markers in the blood, shows promise for early detection and monitoring, potentially improving treatment outcomes.
A Phase III trial found that pemetrexed and cisplatin significantly improved one-year survival rates for mesothelioma patients to 56.5%, compared to 41.9% for those receiving only cisplatin.
A study published in the Journal of the National Cancer Institute found that only 40% of patients with superficial bladder cancer had regular follow-up examinations, despite recommended guidelines. Patient characteristics such as age, ethnicity, and socioeconomic status were independently associated with low-intensity surveillance.
A study found no significant association between exposure to contaminated poliovirus vaccine and the incidence of pleural mesothelioma, a rare lung cancer. Incidence rates increased among older males, but remained stable or decreased in younger age groups.
A new study has shown that patients with mesothelioma, a cancer caused by asbestos exposure, can survive for up to 13-14 months when treated with the drug combination of pemetrexed and carboplatin. This is an improvement over previous treatments, which only offered a six-to-eight-month survival rate.
The use of asbestos continues to pose a significant health risk, particularly in developing and industrialized countries. According to recent data, millions of people worldwide continue to suffer daily exposure to asbestos, leading to an alarming increase in asbestos-related cancers.
Dr. Joseph Testa receives award for his research on mesothelioma, a cancer associated with asbestos exposure. His work aims to understand the genetic alterations that occur in affected cells and potentially develop new treatments.